BrainFulness
Treatment for Major Depression and Anxiety - with NO SIDE EFFECTS!
Company Overview
Snapshot
Founded in September 2015 by Prof. Haim Knobler and Abraham Shoshani, BrainFulness operates with 1–10 employees. The company has raised $55,000 across one funding round from one investor. BrainFulness has developed a working prototype of its technology and secured patent registrations in Israel, the United States, Germany, and Japan.
Business overview
BrainFulness is a Health Tech & Life Sciences company focused on developing a new technology for treating major depression, ADHD, and dementia without side effects. The company's core product is a non-invasive medical device that has undergone clinical trials on chronic, treatment-resistant patients, yielding encouraging results. BrainFulness operates in the Medical Devices, Medical Treatment & Therapeutics sectors, targeting healthcare providers in markets such as Japan, Europe, Israel, and the Americas.
Log in to access full profile ›Company Intelligence Q&A
- When was BrainFulness founded and by whom?
- BrainFulness was founded in September 2015 by Prof. Haim Knobler and Abraham Shoshani.
- What is BrainFulness's primary focus in the healthcare sector?
- BrainFulness is focused on developing a new technology for treating major depression, ADHD, and dementia, emphasizing treatments without side effects.
- Has BrainFulness secured any patents for its technology?
- Yes, BrainFulness has registered patents for its technology in Israel, the United States, Germany, and Japan.
- What is the status of BrainFulness's clinical trials?
- BrainFulness has completed a clinical trial on chronic, treatment-resistant patients, which yielded encouraging results without side effects. The prototype was approved for human use by the Israeli Health Ministry.
- Which markets does BrainFulness target with its products?
- BrainFulness targets markets including Japan, Europe, Israel, and the Americas.